Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The "Pancreatic Cancer - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.
In a significant advancement for the field of oncology, an essential new report has been released, shedding light on the current landscape and potential future of pancreatic cancer treatment. This document compiles an extensive overview of more than 290 companies and their associated 300+ pipeline drugs that are either in clinical or nonclinical stages of development. It provides an indispensable resource for stakeholders looking to understand the burgeoning developments in pancreatic cancer therapeutics.
Emerging Therapies and Clinical Progress
The highlight of the report is the detailed description of emerging drug candidates, showcasing novel approaches such as recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers, and gene therapies. It focuses on the developmental stages of these compounds, providing insights into their mechanism of action, clinical study status, and regulatory designations like Orphan Drug and Fast Track statuses. Several promising candidates such as FibroGen’s Pamrevlumab, in Phase III, Cornerstone Pharmaceuticals’ Devimistat, and AB Science’s Masitinib are outlined in the report, offering hope for improved pancreatic cancer therapies.
Comprehensive Therapeutic Assessment
This insightful report assesses various drugs based on product type, stage, route of administration, and molecule type, providing a detailed panorama of the therapeutic landscape. It also covers inactive pipeline products, elucidating a holistic view of the entire spectrum of developmental activities in the field.
Pipeline Development Activities
Beyond the scientific evaluation, the report delves into the pipeline development activities encompassing strategic collaborations, mergers and acquisitions, and licensing. These operational aspects of drug development are critical in bringing new therapies from the laboratory bench to the patient’s bedside. By analyzing these efforts, the report offers clarity on the commercial and clinical progress within the pancreatic cancer sphere.
Unmet Needs and Drug Impact
The profound impact of emerging drugs on the pancreatic cancer market is discussed, highlighting the potential in addressing the unmet medical needs of patients afflicted with this challenging condition. Therapeutic assessment and drug profiles provide an in-depth understanding of the future direction in which the treatment for pancreatic cancer is moving.
A selection of companies mentioned in this report
- ERYtech Pharma
- Jiangsu HengRui Medicine Co., Ltd.
- FibroGen
- Novartis AG
- AB Science
- Eleison Pharmaceuticals
- Cornerstone Pharmaceuticals
- Panbela Therapeutics
- Taiho Pharmaceutical Co., Ltd.
- Rain Oncology
- Redx Pharma Plc
- Eli Lilly and Company
- Jazz Pharmaceuticals
- Immodulon Therapeutics Ltd
- GSK
- Merck Sharp & Dohme LLC
- Roche
- Helsinn Healthcare SA
- DEKA Biosciences
- Senhwa Biosciences
- Cue Biopharma
- Carisma Therapeutics Inc
- ChemoCentryx
- Boehringer Ingelheim
- Bicara Therapeutics
- Arcus Biosciences
- Mainline Biosciences
- Beijing Imunopharm Technology Co., Ltd.
- TriSalus Life Sciences
- Ono Pharmaceutical
- Exelixis
- Wellmaker Bio
- Pionyr Immunotherapeutics
- Ability Pharmaceuticals SL
- A2 Biotherapeutics
- Klus Pharma Inc.
- Nelum Corp
- Crystal Genomics Inc.
- Elicio Therapeutics
- Turning Point Therapeutics
- Immuneering Corporation
- pHion Therapeutics Ltd.
- AC BioScience
- TheraVectys
- Opna Bio
- Cytuvax
- Eureka Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/s3jlwl
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
